Recently, there has been a growing interest in alternative therapies and in the therapeutic use of natural products for the treatment of diabetes. Therefore, in this study, we investigated the hypoglycemic and hypolipidemic effects of brown algae, Padina arborescens, in an animal model of type 2 diabetes. For 6 weeks, male C57BL/KsJ-db/db mice were administrated either control diet with no treatment or were treated with rosiglitazone (RG; 0.005%, w/w) or P. arborescens extract (PAE; 0.5%, w/w). At the end of the experimental period, the blood glucose levels, glycosylated hemoglobin levels, and plasma insulin levels were significantly lower in the RG and PAE groups compared with the control group. In addition, glucose tolerance was significantly improved in the RG and PAE groups. The homeostatic index of insulin resistance was lower in the RG and PAE groups than the diabetic control group. Also, the total cholesterol, LDL-cholesterol, triglyceride, and free fatty acid levels were lower in the PAE group than in the control group, whereas the HDL-C level was higher in the PAE group. Supplementation with PAE significantly lowered hepatic glucose-6-phosphatase and phosphoenolpyruvate carboxykinase activities, and increased glucokinase activity in the liver. Consequently, these results suggest that PAE may be beneficial in improving insulin resistance, hyperglycemia, and dyslipidemia in type 2 diabetics.
Get full access to this article
View all access options for this article.
References
1.
AdamsGG, ImranS, WangW, et al.: The hypoglycaemic effect of pumpkins as anti-diabetic and fuctional medicines. Food Res Int, 2011; 44:862–867.
2.
ZimmetP, AlbertiK, ShawJ: Global and societal implications of the diabetes epidemic. Nature, 2001; 414:782–787.
3.
TaskinenMR: Diabetic dyslipidaemia: From basic research to clinical practice. Diabetologia, 2003; 46:733–749.
4.
DeFronzoRA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med, 1999; 131:281–303.
5.
ChangMS, OhMS, KimDR, et al.: Effects of Okchun-San, a herbal formulation, on blood glucose levels and body weight in a model of type 2 diabetes. J Ethnopharmacol, 2006; 103:491–495.
6.
ChandiniSK, GanesanP, BhaskarN: In vitro antioxidant activities of three selected brown seaweeds of India. Food Chem, 2008; 107:707–713.
7.
KangJY, KhanMN, ParkNH, et al.: Antipyretic, analgesic, and anti-inflammatory activities of the seaweed Sargassum fulvellum and Sargassum thunbergii in mice. J Ethnopharmacol, 2008; 116:187–190.
8.
FukuyamaY, KodamaM, MiuraI, et al.: Structure of an anti-plasmin inhibitor, eckol, isolated from the brown alga Ecklonia kurome Okamura and inhibitory activities of its derivatives on plasma plasmin inhibitors. Chem Pharm Bull, 1989; 37:349–353.
9.
LeeSH, MinKH, HanJS, et al.: Effects of brown alga, Ecklonia cava on glucose and lipid metabolism in C57BL/KsJ-db/db mice, a model of type 2 diabetes mellitus. Food Chem Toxicol, 2012; 50:575–582.
10.
ChungHY, MaWC, AngPOJr., et al.: Seasonal variations of bromophenols in brown algae (Padina arborescens, Sargassum siliquastrum, and Lobophora variegate) collected in Hong Kong. J Agric Food Chem, 2003; 51:2619–2624.
11.
ParkMH, HanJS: Hypoglycemic effect of Padina arborescens extract in streptozotocin-induced diabetic mice. Prev Nutr Food Sci, 2012; 17:239–244.
12.
HaffnerSM, MiettinenH, SternMP: The homeostasis model in the San Antonio heart study. Diabetes Care, 1997; 20:1087–1092.
13.
KatzA, NambiSS, MatherK, et al.: Quantitative insulin sensitivity check index: A simple, accutate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab, 2000; 85:2402–2410.
14.
HulcherPH, OlesonWH: Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res, 1973; 14:625–631.
15.
DavidsonAL, ArionWJ: Factors underlying significant underestimations of glucokinase activity in crude liver extracts: Physiological implications of higher cellular activity. Arch Biochem Bophys, 1987; 253:156–167.
16.
AlegreM, CiudadCJ, FillatC, et al.: Determination of glucose-6-phosphatase activity using the glucose dehydrogenase-coupled reaction. Anal Biochem, 1988; 173:185–189.
17.
BentleLA, JardyHA: Interaction of anions and divalent metal ions with phosphopyruvate carboxykinase. J Biol Chem, 1976; 251:2916–2921.
18.
SeifterS, DaytonS, NovicB, et al.: The estimation of glycogen with the anthrone reagent. Arch Biochem, 1950; 25:191–200.
19.
BuseJB: Type 2 diabetes mellitus in 2010: Individualizing treatment targets in diabetes care. Nat Rev Endocrinol, 2011; 7:67–68.
20.
KimKR, LeeJH, KimSJ, et al.: A novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. Biochem Pharmacol, 2006; 72:446–454.
21.
KodamaH, FujitaM, YamazakiM, et al.: The possible role of age-related increase in the plasma glucagon/insulin ratio in the enhanced hepatic glucomeogemesis and hyperglycemia in genetically diabetic (C57BL/KsJ-db/db) mice. Jpn J Pharmacol, 1994; 66:281–287.
GinsbergH, KimmerlingG, OlefskyJM, et al.: Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest, 1975; 55:454–461.
24.
EvansAJ, KrenzAJ: Insulin resistance and β-cell dysfunction as therapeutic targets in type 2 diabetes. Diabetes Obes Metab, 2001; 3:219–229.
25.
FujiwaraT, WadaM, FukudaK: Characterization of CS-045, a new oral antidiabetic agent: Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism, 1991; 40:1213–1218.
26.
MuniyappaR, LeeS, ChenH, et al.: Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab, 2008; 294:15–26.
27.
HawkinsM, TonelliJ, KishoreP, et al.: Contribution of elevated free fatty acid levels to the lack of glucose effectiveness in type 2 diabetes. Diabetes, 2003; 52:2748–2758.
28.
DaimonM, OizumiT, SaitohT, et al.: Decreased serum levels of adiponection are a risk factor for the progression to type 2 diabetes in the Japanese population. Diabetes Care, 2003; 26:2015–2020.
29.
ZietzB, HerfarthH, PaulG, et al.: Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett, 2003; 545:103–104.
30.
BakogianniMC, KalofoutisCA, SkenderiKI, et al.: Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-isulin-dependent diabetics with coronary artery disease. J Diabetes Complications, 2001; 15:265–269.
31.
BasuA, BasuR, ShahP, et al.: Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: Additional evidence for a defect in hepatic glucokinase activity. Diabetes, 2001; 50:1351–1362.
32.
GuignotL, MithieuxG: Mechanisms by which insulin, associated or not with glucose, may inhibit hepatic glucose production in the rat. Am J Physiol, 1999; 277:984–989.
33.
BrocklehurstKJ, PayneVA, DaviesRA, et al.: Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes, 2004; 53:535–541.
34.
HersHG, HueL: Gluconeogenesis and related aspects of glycolysis. Annu Rev Biochem, 1983; 52:617–653.
